SCHEMBL16570895

SCHEMBL16570895

CN(c1ccccc1Cn1ccc2cnc(Nc3ccc4c(c3)C(=O)NC4=O)nc21)S(C)(=O)=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 16/20 0.49
▸ PTK2B Q14289 5/20 0.49
▸ AURKA O14965 2/20 0.46
▸ BRD4 O60885 1/20 0.46
▸ JAK2 O60674 11/20 0.45
▸ JAK3 P52333 9/20 0.45
▸ SRPK1 Q96SB4 2/20 0.45
▸ DCLK1 O15075 1/20 0.45
▸ PDPK1 O15530 1/20 0.45
▸ ROCK2 O75116 1/20 0.45
▸ PRKD3 O94806 1/20 0.45
▸ MAP4K4 O95819 1/20 0.45
▸ EGFR P00533 1/20 0.45
▸ NTRK1 P04629 1/20 0.45
▸ PRKCG P05129 1/20 0.45
▸ LCK P06239 1/20 0.45
▸ FYN P06241 1/20 0.45
▸ CDK1 P06493 1/20 0.45
▸ LYN P07948 1/20 0.45
▸ RET P07949 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16571049 0.89 SRPK1 (0.52) PTK2PTK2BAURKAJAK2JAK3
SCHEMBL16581005 0.86 PTK2 (0.51) PTK2PTK2BAURKABRD4JAK2
SCHEMBL16571003 0.84 PTK2 (0.65) PTK2PTK2BAURKABRD4JAK2
SCHEMBL16570232 0.84 PTK2 (0.50) PTK2PTK2BAURKABRD4JAK2
SCHEMBL16571159 0.83 PTK2 (0.56) PTK2PTK2BAURKABRD4JAK2
SCHEMBL16570591 0.83 JAK3 (0.45) PTK2PTK2BAURKABRD4JAK2
SCHEMBL16571027 0.82 PTK2 (0.50) PTK2PTK2BAURKABRD4JAK2
SCHEMBL16570153 0.82 STAT6 (0.48) PTK2PTK2BAURKABRD4JAK2
SCHEMBL16580780 0.81 PTK2 (0.48) PTK2PTK2BAURKAJAK2JAK3
SCHEMBL16570503 0.81 PTK2 (0.51) PTK2AURKAJAK2JAK3SRPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN PTK2 2/4885PTK2B 13/4885AURKA 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback